STOCK TITAN
  1. Home
  2. News
  3. CHRS

Coherus BioSciences, Inc. - CHRS STOCK NEWS

Welcome to our dedicated page for Coherus BioSciences news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus BioSciences stock.

Coherus BioSciences, Inc. (NASDAQ: CHRS) is a leading commercial-stage biopharmaceutical company dedicated to improving patient access to high-quality, life-changing biologic medicines. Established in 2010 and headquartered in the San Francisco Bay Area, Coherus specializes in developing biosimilars and innovative immuno-oncology therapies to treat various chronic and life-threatening diseases.

Coherus' core business revolves around providing biosimilar therapeutics that are designed to replace existing branded biologics, thereby reducing healthcare costs. The company's biosimilar portfolio includes FDA-approved products like UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), which is set to launch in the US in 2023. These products help manage conditions such as cancer and autoimmune diseases, expanding patient access to essential treatments.

Recently, Coherus completed the divestiture of its ophthalmology franchise, CIMERLI®, to Sandoz, Inc. for $170 million. This move allows Coherus to focus more intently on its immuno-oncology pipeline, which includes the promotion of LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor approved for nasopharyngeal carcinoma. The company's strategy includes advancing its novel immuno-oncology candidates like CHS-114 and CHS-1000, which are in various stages of clinical development targeting solid tumors.

Financially, Coherus is leveraging the revenue from its biosimilar products to fund its immuno-oncology research and development. The company collaborates with global pharmaceutical partners across Europe, Asia, and Latin America, enhancing its market presence and resource capabilities.

Key updates include the successful preclinical data presentation for CHS-1000 at the 2024 AACR Annual Meeting, showcasing its potential to reverse immunosuppression in the tumor microenvironment. Moreover, the Cancer Research Institute (CRI) has selected LOQTORZI for combination studies to explore its efficacy in drug-resistant cancers, further solidifying Coherus' commitment to pioneering cancer therapy advancements.

Led by a team of seasoned industry veterans, Coherus BioSciences aims to become a global leader in the biosimilar and immuno-oncology markets, continually striving to develop therapies that improve patient outcomes and broaden access to high-quality medical treatments.

News

Coherus Announces U.S. Launch of LOQTORZI™

Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) launches LOQTORZI, the first and only FDA-approved treatment for NPC in all lines of therapy. LOQTORZI is indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status. The drug is now available for purchase through select specialty distributors in the United States. LOQTORZI has demonstrated impressive clinical benefits, including progression-free survival (PFS) and overall survival (OS), offering new hope for extended survival to patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced FDA approval of UDENYCA ONBODY, an on-body injector for pegfilgrastim, with a unique retractable needle mechanism and five-minute delivery time. The device is designed to maximize safety and comfort for cancer patients receiving pegfilgrastim, offering a novel administration option for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
fda approval
-
News

Coherus BioSciences Announces New Employment Inducement Grants

Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) granted options to purchase 192,000 shares of common stock to five newly hired employees. One executive was granted an option to purchase 150,000 shares, and four non-officer employees were granted options to purchase 42,000 shares. The options were granted under the 2016 Employment Commencement Incentive Plan approved by the Company's board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
none
News

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

Rhea-AI Summary
Coherus BioSciences, ticker symbol CHRS, announced that LOQTORZI is recommended as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy, and as the only preferred regimen in subsequent lines of therapy. LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News

Coherus BioSciences Announces CFO Transition Plans

Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) announced the resignation of Chief Financial Officer McDavid Stilwell, with his last day of employment set for December 31, 2023. The company will appoint an interim Principal Financial Officer while searching for a new CFO. Coherus aims to achieve its 2024 goals and beyond, with a focus on new product launches and immuno-oncology pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
-
News

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) announced positive data from the ongoing Phase 1b/2 clinical trial of casdozokitug (casdozo), a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress. The data supports continued evaluation of casdozo in combination with anti-PD-1 antibody treatments, including ongoing Phase 2 cohort of casdozo with toripalimab in treatment refractory NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
clinical trial
News

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Rhea-AI Summary
Coherus Biosciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd (1877, 688180) announced the publication of the final overall survival results from the pivotal JUPITER-02 study, revealing a 37% reduction in the risk of death in NPC patients treated with toripalimab plus chemotherapy versus chemotherapy alone. LOQTORZI is the first FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
clinical trial
-
News

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary
Coherus BioSciences reported a 27% increase in net revenue to $74.6 million for the quarter ended September 30, 2023. CIMERLI® net sales rose 50% to $40 million, while UDENYCA® net sales increased to $33 million. The FDA approved LOQTORZI™ for the treatment of nasopharygeal carcinoma, with a commercial launch planned for Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.23%
Tags
earnings
-
News

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary
Coherus BioSciences presents data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC. The data support the development of their anti-IL-27 antibody casdozokitug, anti-CCR8 antibody CHS-114, and anti-PD-1 antibody LOQTORZI™. The data demonstrate distinct IL-27-mediated gene expression, the role of CCR8+ Tregs in the tumor microenvironment, and the enhanced clinical efficacy of LOQTORZI™ in combination with chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
none
News

Coherus BioSciences to Participate at Upcoming November Investor Conferences

Rhea-AI Summary
Coherus BioSciences, Inc. announced that senior management will participate in several investor conferences, including Truist Securities BioPharma Symposium, UBS Biopharma Conference, and Evercore ISI HealthCONx Conference. The presentations will be webcasted and available on the Coherus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
conferences

FAQ

What is the current stock price of Coherus BioSciences (CHRS)?

The current stock price of Coherus BioSciences (CHRS) is $1.28 as of January 23, 2025.

What is the market cap of Coherus BioSciences (CHRS)?

The market cap of Coherus BioSciences (CHRS) is approximately 149.8M.

What does Coherus BioSciences specialize in?

Coherus BioSciences specializes in developing high-quality biosimilar therapeutics and innovative immuno-oncology therapies to treat chronic and life-threatening diseases.

Where is Coherus BioSciences headquartered?

Coherus BioSciences is headquartered in the San Francisco Bay Area.

What are some of Coherus' FDA-approved products?

Coherus markets UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), along with LOQTORZI™ (toripalimab-tpzi), a PD-1 inhibitor.

What recent transactions has Coherus BioSciences completed?

Coherus recently sold its CIMERLI® ophthalmology franchise to Sandoz, Inc. for $170 million.

How does Coherus BioSciences fund its immuno-oncology research?

Coherus leverages revenue generated from its diversified portfolio of FDA-approved biosimilars to fund its immuno-oncology research.

What is the significance of Coherus' partnership with the Cancer Research Institute?

The Cancer Research Institute has selected LOQTORZI for studies on drug-resistant cancers, highlighting the potential of Coherus' immuno-oncology treatments to advance patient care.

Which markets do Coherus' partnerships cover?

Coherus has commercialization partnerships with global pharmaceutical companies in Europe, Asia, and Latin America.

What recent achievements has Coherus made in its clinical pipeline?

Coherus presented promising preclinical data for CHS-1000 at the 2024 AACR Annual Meeting, demonstrating its potential to reverse tumor immunosuppression.

Who are the key figures in Coherus BioSciences' leadership?

Coherus is led by a team of industry veterans with decades of experience in pioneering biologics companies, including Chairman and CEO Denny Lanfear.

What is the focus of Coherus' CHS-114 clinical trials?

CHS-114, an anti-CCR8 antibody, is being evaluated in Phase 1 trials for its ability to selectively deplete tumor-resident regulatory T cells, enhancing anti-tumor immune response.
Stock CHRS logo
Coherus BioSciences, Inc.

Nasdaq:CHRS

CHRS Rankings

#4130 Ranked by Market Cap
N/A Ranked by Dividends

CHRS Stock Data

149.84M
110.62M
1.38%
70.28%
26.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
REDWOOD CITY